Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)

• Status: Completed
• Trial end date: 2014-03-01

Summary

The objective of this trial is to evaluate the efficacy and safety of two different treatment regimens with BI 201335, both in combination with PegIFN/RBV) as compared to standard of care (SOC) with PegIFN/RBV alone.

• Phase: Phase 3

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Interferon-alpha; Interferons; Ribavirin